Key Takeaways
- Aphea.Bio has entered a strategic partnership with Bayer to co-develop bioinsecticides targeting sap-sucking insects, a category of crop pests with limited effective control options.
- The collaboration combines Aphea.Bio's proprietary pipeline of bioactive metabolites derived from microbial strains with Bayer's global commercialization and development capabilities.
- Initial focus covers fruit crops including pome, stone fruit, citrus, and grapes, with additional potential in vegetables and row crops such as cotton and soybean.
- The partnership agreement was signed at a ceremony in Monheim on June 9, 2026; financial terms have not been disclosed.
- Milestone progression is structured around clear gates covering efficacy, safety, producibility, and regulatory pathway clarity.
Aphea.Bio and Bayer Target a Gap in Crop Protection
Aphea.Bio has announced a strategic research partnership with Bayer to accelerate the development of bioinsecticides aimed at sap-sucking insects — a class of agricultural pests responsible for significant economic damage to crops worldwide. The agreement was formalized at a signing ceremony in Monheim on June 9, 2026.
Sap-sucking insects present a persistent challenge for growers. Regulatory restrictions and growing resistance to certain conventional insecticide classes have narrowed the available toolbox, creating demand for effective biological alternatives. Aphea.Bio has built its platform around addressing precisely this gap, screening thousands of microbial strains to identify bioactive metabolites with insecticidal properties and advancing the most promising candidates through structured development phases.
What Aphea.Bio Brings to the Collaboration
The Belgian agbiotech company’s core proposition centers on a category it describes as bioinsecticides derived from microbial metabolites — products designed to combine the efficacy profile of biological solutions with the handling characteristics and shelf-life of non-living formulations. This positions them differently from live microbial products, which can face practical limitations in field deployment.
Aphea.Bio’s contribution to the partnership covers lead identification, characterization, and early-stage development, drawing on its proprietary R&D pipeline. The company’s process involves systematic screening followed by development phases focused on safety, efficacy, and market-ready specifications — work that feeds directly into the joint pipeline being created with Bayer.
“The bioinsecticide market has been waiting for a partnership like this. Bayer’s decision to collaborate with us reflects confidence in our team’s ability in developing high-quality bioinsecticide leads, while they bring the capability to take these solutions to millions of farmers. Together, we can deliver crop protection that actually works on a global scale, addressing pests that currently have few effective options,” said Isabel Vercauteren, CEO of Aphea.Bio.
Bayer’s Role: Scale and Commercialization
Bayer enters the collaboration bringing its global market reach and development infrastructure in crop science. The partnership is structured to leverage these complementary strengths — with Aphea.Bio providing the biological innovation pipeline and Bayer enabling the pathway from validated prototype to commercial product at scale.
“Through this research partnership with Aphea.Bio, we help broaden the crop protection toolbox and accelerate the development of innovative, effective and scalable biological solutions that meet the evolving needs of growers,” said Benoit Hartmann, Insights, Innovation & Partnerships Lead in Bayer’s Crop Science division.
Target Crops and Development Pathway
The initial scope of the collaboration targets fruit crops — specifically pome fruit, stone fruit, citrus, and grapes — with scope to expand into vegetables and row crops including cotton and soybean. These crops are among those most affected by sap-sucking pest pressure and face some of the most constrained conventional control options.
Under the agreement, both companies will work jointly to advance prototype products through field validation and early regulatory engagement. Progress is tied to defined milestone gates covering efficacy, safety, producibility, and regulatory pathway clarity. The financial terms of the deal have not been disclosed.
1 Comment